A Potent Oncolytic Herpes Simplex Virus for Therapy of Advanced Prostate Cancer
Abstract
The safety of the first generation oncolytic HSV has been well documented. Retaining this safety - profile is mandatory for potential clinical applications of the fusogenic oncolytic HSV. The fusogenic oncolytic HSV has thus been uniquely designed and constructed as such that the syncytia formation from the virus requires viral DNA replication in the targeted cells. As oncolytic HSV can only initiate - viral replication in tumor cells, this restricts the syncytial formation from virus infection to malignant cells only. Therefore fusogenic oncolytic HSV should be no more toxic than its parental construct. Nonetheless, we proposed in the year 2 of this funded project to conduct extensive studies in animal models to confirm its safety in vivo. The results obtained so far from these experiments have demonstrated that the fusogenic oncolytic HSV is indeed not significantly more toxic than the nonfusogenic virus, confirming our original hypothesis that the fusogenic virus is safe for potential clinical application.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2005
- Accession Number
- ADA442299
Entities
People
- Xiaoliu Zhang
Organizations
- Baylor College of Medicine